Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2011 Oct 25; 105(9): 1352–1361.
Published online 2011 Oct 4. doi:  10.1038/bjc.2011.388
PMCID: PMC3241557

Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma



Combination of age at diagnosis, stage and MYCN amplification stratifies neuroblastoma into low-risk and high-risk. We aimed to establish whether a microRNA (miRNA) signature could be associated with prognosis in both groups.


Microarray expression profiling of human miRNAs and quantitative reverse-transcriptase PCR of selected miRNAs were performed on a preliminary cohort of 13 patients. Results were validated on an independent cohort of 214 patients. The relationship between miRNA expression and the overall or disease-free survival was analysed on the total cohort of 227 patients using the log-rank test and the multivariable Cox proportional hazard model.


A total of 15 of 17 miRNAs that discriminated high-risk from low-risk neuroblastoma belonged to the imprinted human 14q32.31 miRNA cluster and two, miR-487b and miR-410, were significantly downregulated in the high-risk group. Multivariable analyses showed miR-487b expression as associated with overall survival and disease-free survival in the whole cohort, independently of clinical covariates. Moreover, miR-487b and miR-410 expression was significantly associated with disease-free survival of the non-MYCN-amplified favourable neuroblastoma: localised (stage 1, 2 and 3) and stage 4 of infant <18 months.


Expression of miR-487b and miR-410 shows predictive value beyond the classical high-/low-risk stratification and is a biomarker of relapse in favourable neuroblastoma.

Keywords: neuroblastoma, non-MYCN-amplified, microRNA, 14q32.31 locus, prognosis

Neuroblastoma, the most common solid tumour of childhood, affects very young children (median age: 17 months at diagnosis). Although neuroblastoma accounts for the highest morbidity and mortality among childhood cancers, some rare forms spontaneously regress, a unique phenomenon in human oncology. Moreover, the wide spectrum of clinical behaviours of neuroblastoma constitutes a model of tumour heterogeneity. Stage, age and MYCN amplification represent the basic parameters used for risk stratification for management and treatment of the disease (Maris, 2010). Last decade has dealt with the search of tumour-oriented genomic information that refines pronostic classification of patients. Hyperdiploidy and several genomic aberrations, among which gain or loss of whole chromosomes and intra-chromosomal alterations including loss of 1p, 11q, 14q and gain of 17q (Ambros et al, 2003; Maris, 2010) have finally led to pan-genomic DNA analyses whose prognostic values are under investigation (Janoueix-Lerosey et al, 2009; Ambros et al, 2011). According to the basic clinical stratification, paediatric oncologists distinguish two groups of neuroblastoma at diagnosis, the optimal age cutoff being 18 months (Cohn et al, 2009) The low-risk group consists of non-MYCN-amplified tumours that occur either as localised forms (stage 1, 2 and 3) or as metastatic forms in the children of age <18 months (stage 4 and 4S). The high-risk group comprises all MYCN-amplified neuroblastoma regardless of stage and age of the child, and non-MYCN-amplified stage 4 neuroblastoma for children of age ⩾18 months. If the low-risk group elicits up to 90% survival (De Bernardi et al, 2009; Rubie et al, 2011), the high-risk group shows aggressive tumours leading to death very frequently with a survival around 35% at 5 years. However, relapse for low-risk patients constitutes a current concern. With regards to treatment, low-risk patients benefit essentially of surgery and induction chemotherapy to improve response rates while high-risk patients undergo a systematic induction chemotherapy before surgery, high-dose chemotherapy and retinoic acid-based maintenance treatments (Matthay et al, 1999; Valteau-Couanet et al, 2005). Thus, in terms of prognosis, current clinical issues are to predict survival for the high-risk group and disease-free survival for the low-risk group in order to optimise therapy. It is commonly admitted that a better knowledge of molecular and genetic mechanisms could be helpful in these respects.

The use of array technologies to characterise microRNAs (miRNAs) has enabled discovering unique miRNA expression patterns related to clinical features of several cancers. The miRNAs are endogenous small non-coding RNAs that regulate gene expression by promoting mRNA degradation or preventing translation by imperfect sequence-specific interaction with the 3′-untranslated region of mRNAs. Deregulation of miRNA expression at a number of loci has already been reported in neuroblastoma. Expression profiling analysis of 157 miRNA's loci in neuroblastoma led to the identification of 32 loci that were differentially expressed in favourable and unfavourable tumour subtypes indicating a potential role of miRNAs in neuroblastoma pathogenesis (Chen and Stallings, 2007). Many of these loci are significantly underexpressed in tumours with MYCN amplification (Schulte et al, 2008; Bray et al, 2009). By deep sequencing analysis of five favourable and five unfavourable MYCN-amplified neuroblastoma, Schulte et al (2010) reported the underexpression of 20 miRNAs. Lin et al (2010) found a global downregulation of miRNA expression in advanced neuroblastoma, and identified 27 miRNAs that clearly distinguish low- from high-risk patients.

To our knowledge, no data are available on the possibility to use deregulated specific miRNA as predictors of relapse for low-risk patients and survival for high-risk patients. In the present work, we show that the downregulation of miR-487b and miR-410, two miRNAs located at the 14q32.31 locus, is associated with the outcome of neuroblastoma in terms of both overall survival and relapse whether MYCN is amplified or not. Importantly, our results point out that underexpression of these two miRNAs could predict relapse among neuroblastoma currently classified as low-risk.

Materials and methods

Tumour collection

Tumour samples from a retrospective cohort of 227 patients staged according to the International Neuroblastoma Staging System (Brodeur, 2003) were gathered between 1987 and 2009 at the Institut Gustave Roussy (n=215) and at the Centre Leon Bérard (n=12) with the approval of the appropriate ethic committees and according to the national law on the protection of people taking part in biomedical research. Primary tumour tissues, obtained from patients either by true-cut or after surgery, were immediately snap frozen before being stored in liquid nitrogen until nucleic acids extraction.

Tumour cryosections and total RNA extraction

The first and last cryosections were used to select tumour tissues with a malignant tumour cell content of ⩾60%. (Ambros et al, 2003; Benard et al, 2008). Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. Nucleic acid concentration and purity were determined by using Nanodrop ND-1000 (Nanodrop, Wilmington, DE, USA), while quality was verified with a 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA, USA).

miRNA microarray expression analysis

Each sample was prepared according to the Agilent's miRNA Microarray System protocol. Total RNA (100 ng) was labelled and hybridised to Agilent human miRNA 8 × 16-k microarrays (v3) containing 851 human and 88 human viral miRNAs each replicated 16 times, according to the manufacturer's instructions. Agilent miRNA assays integrate eight individual microarrays on a single glass slide. Each microarray includes ∼15-k features containing probes sourced from the miRBASE public database, release 13.0 (Griffiths-Jones et al, 2008). The probes were 40–60-mer oligonucleotides directly synthesised on the array with a special design to cope with the small size of miRNA. Indeed, each probe was composed of three features: hybridisation sequence (10–20 nucleotides), a G residue at 5′ end of the hybridisation sequence that complement the 3′ end C residue introduced in labelling and an extended 5′ hairpin abutting on the probe–target region to increase target size and miRNA specificity. The additional G–C pair in the probe–target interaction region stabilises targeted miRNA relative to homologous RNAs. The array also contained a set of repeated positive and negative controls. All processing methods used for miRNA analyses were performed on the Cy3 Median Signal from Agilent Feature Extraction raw data files in R, using functions and package collected in the Bioconductor project (Gentleman et al, 2004) as well as customed written routines. Flagged spots as well as control spots were systematically removed, and data were log2 transformed. A quantile normalisation was then performed using the normalizeBetweenArray function from R package ‘LIMMA' (Smyth et al, 2005) from the Bioconductor project. The median of each probe for a given miRNA was computed and the corresponding value was assigned to the miRNA. Data were then filtered according to the maximum number of missing values allowed for each miRNA (30%).

Unsupervised hierarchical clusters were computed using the ‘dist' function from R, using the ‘Euclidian' method as distance measure. The hierarchical clustering was performed with the ‘hclust' function from R using the distance matrix previously computed and the ward method.

To assess differentially expressed miRNAs, we first estimated the fold changes and standard errors between two groups of samples by fitting a linear model for each miRNA with the ‘lmFit' function of LIMMA package (Smyth et al, 2005). Then, we applied an empirical Bayes smoothing to the standard errors to the linear model previously computed with ‘eBayes' function of LIMMA. To extract a table of the top-ranked genes from the linear model fit, we used top Table function from LIMMA. The results were saved in a table file format.

miRNA real-time reverse-transcription PCR

Total RNA (10 ng) was reverse transcribed on the PTC-100 (MJ Research Inc., Waltham, MA, USA) using the stem-loop reverse transcription (TaqMan MicroRNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA) for three selected miRNAs from the miRNA microarray analysis, hsa-miR-409-3p, hsa-miR-410 and hsa-miR-487b, vs RNU-44 (small nuclear RNA) as a control. Real-time PCR amplifications run in duplicate using 2 × FastStart Universal Probe Master (Roche, Mannheim, Germany) were performed on the StepOnePlus RealTime PCR System (Applied Biosystems) according to the MIQE guidelines (Bustin et al, 2009). Samples that lacked either a template or reverse transcriptase were used as controls. The relative expression of each miRNA was calculated according to the comparative 2−ΔΔCt quantification method where ΔCt=Ct(sample)−Ct(normaliser) and ΔΔCt=ΔCt(sample)−ΔCt(calibrator) (Livak and Schmittgen, 2001). RNU 44 was used as a normaliser and IGR-N-835 cell line (Bettan-Renaud et al, 1989) as the miRNA expression level reference, sample and reference being amplified in separate wells.

Statistical analysis

The quantitative reverse-transcriptase PCR (qRT-PCR) data were analysed using GraphPad Prism software to generate scatter plots, and two-tailed Student t-test was used to compare the different neuroblastoma groups. The association between various clinical characteristics and miRNA expression levels were examined by the two-tailed Fisher's exact test.

To determine if miRNA expressions were related significantly to overall and disease-free survival of patients (endpoint of cancer-specific death and relapse, respectively), we performed several analyses. Kaplan–Meier survival curves and univariate and multivariable Cox proportional hazards analyses were performed with SAS software. To generate survival curves, we converted continuous miRNA expression levels measured by qRT-PCR to a dichotomous variable, using as cutoff the expression level of IGR-N-835 cell line taken as one. This cutoff was found to be very close to those computed for the expression of miRNAs that best discriminate patients for overall survival (the time from the diagnosis to the date of death of disease) and for disease-free survival (the time from diagnosis to the date of first appearance of relapse or death). This procedure enabled division of samples into two levels with high and low expression of miRNA (over and under the cutoff point, respectively). We compared survival curves by log-rank test and judged P<0.05 significant. We undertook univariate Cox proportional hazards regression in SAS software and judged a significance if P<0.05. We examined the joint effect of covariates with Cox proportional hazards regression to ascertain whether miRNAs were independent prognostic factors. Age was dichotomised into groups, less and over 18 months. Stage was dichotomised on the whole neuroblastoma cohort on the basis of metastatic progression, stage 1, 2, 3 vs stage 4. Stage 4S was included in stage 1, 2, 3 groups because the prognosis of these patients is usually considered as good.

For all miRNAs, patients were categorised into groups with high and low expression, as described above. All variables with P<0.05 in univariate analyses were selected in the multivariable model. To evaluate the predictive ability of the markers, sensitivity and specificity were estimated within 2, 5 and 8 years because the event of interest is time-dependent (Heagerty et al, 2000). Sensitivity was defined as the probability that a patient having low expression of 14q32.31 miRNA (below the cutoff) to be in the high-risk group and specificity as the probability that a patient with high expression of 14q32.31 miRNA (above the cutoff) to be in the low-risk group.


miRNA expression profiling from patients with opposite outcome

The search for a miRNA expression signature associated with patient outcome was first performed on a preliminary cohort of 13 primary neuroblastoma tumours whose risk at diagnosis was defined according to clinical criteria (age at diagnosis and stage) and MYCN amplification (Figure 1A). This consisted of neuroblastoma with opposite outcomes, namely five low-risk obtained from infants (median age: 3.8 months, median follow-up: 112.6 months) and eight high-risk from children (median age: 27.5 months, median follow-up: 14.8 months). Consistent with this risk stratification, comparative genomic hybridisation array (CGHa) profiles showed chromosomal alterations that were numerical in low-risk and segmental in high-risk neuroblastoma (Supplementary Table 1). As shown in Figure 1B, unsupervised hierarchical clustering on the 851 human and 88 human viral miRNA expression profiling discriminated high-risk from low-risk tumours except for two tumours classified as high risk (patients 600 and 2232). Among the 851 human miRNAs, 50 were differentially expressed in the high-risk relatively to the low-risk group (raw P-values <0.05), that is, 37 were downregulated and 13 were upregulated (Supplementary Table 2). In accordance with Chen and Stallings (2007), miRNA-181a and miRNA-181b were found to be upregulated. None of the upregulated miRNAs elicited a significant adjusted P-value, whereas 17 downregulated miRNAs displayed highly significant adjusted P-values as well as the highest fold change. Strikingly, 15 of the 17 downregulated miRNAs were located at the chromosome 14q32.31 locus (Table 1), a locus that harbours the largest miRNA cluster identified so far in the human genome (Seitz et al, 2004). This observation led us to perform an unsupervised hierarchical clustering on the totality of miRNAs encoded at locus 14q32.31. Results efficiently discriminated all high-risk, including patients 600 and 2232, from low-risk (Figure 2 and Supplementary Table 3). As loss of 14q heterozygosity in neuroblastoma was reported (Thompson et al, 2001), we performed CGHa that ruled out the possibility that the low expression of 14q32.31 miRNAs in high-risk neuroblastoma was the result of a genomic copy loss (Supplementary Table 1). To confirm microarray data obtained from the preliminary cohort, qRT-PCR was applied to three downregulated 14q32.31 miRNAs, namely miR-487b, miR-410 and miR-409-3p, that were selected because miR-487b and miR-410 showed the highest fold changes and adjusted P-values while miR-409-3p ranked in a mean position for both fold change and P-value (Table 1). The qRT-PCR analysis confirmed a significant downregulation of these three miRNAs in high-risk compared with low-risk neuroblastoma (Supplementary Table 4). These results suggested a possible association between underexpression of miR-487b, miR-410 and miR-409-3p and risk of death.

Figure 1
Patients characteristics and tumour clustering using miRNA expression profiling. (A) Clinical main characteristics of patients from the preliminary cohort. INSS: International Neuroblastoma Staging System. Present status February 2011: A, Alive; DoD, ...
Figure 2
Summary heat map showing the clustering based on 14q32.31 miRNA cluster. Data are represented as two dendrograms. The vertical dendrogram indicates patient sample with closest miRNA expression patterns. The horizontal dendrogram indicates miRNA with closest ...
Table 1
Differential miRNA expression between low- and high-risk neuroblastoma with adjusted P-value <0.05

Validation of the low expression of 14q32.31 miRNAs associated with high-risk neuroblastoma

To validate the low expression of 14q32.31 miRNAs potentially associated with risk of death, an independent cohort of 214 patients (142 classified as low-risk and 72 as high-risk) was analysed. The main clinical features of patients and tumour characteristics are described in Table 2 and Supplementary Table 4. The expression levels of miR-487b, miR-410 and miR-409-3p were evaluated by qRT-PCR (Supplementary Table 4) relatively to the IGR-N-835 cell line (Bettan-Renaud et al, 1989). As presented in the scatter plots, mean expression levels of the three miRNAs were significantly lower in high-risk than in low-risk tumours (Figure 3A). Next, the data were stratified according to age, stage and MYCN amplification on the whole cohort of 227 tumours (13 of the preliminary cohort and 214 of the validation set) (Figure 3B). As compared with the non-MYCN-amplified localised (stage 1, 2, and 3) tumours, the mean expression levels of miR-487b and miR-410, but not of miR-409-3p, were significantly downregulated in the two high-risk neuroblastoma subgroups, that is, MYCN-amplified (P<0.01) and non-MYCN-amplified stage 4 children aged ⩾18 months (P<0.04). These results revealed that the low expression level of miR-487b and miR-410 was significantly associated with the high-risk groups, independently of MYCN amplification. Regarding the non-MYCN-amplified tumours, it is noteworthy that the average expression values for the three miRNA from stage 4 patients <18 months (n=11) were higher than those ⩾18 months (n=49) (Figure 3B). The difference was significant for miR-410 and miR-409-3p (P=0.0321 and 0.0474, respectively) but not for miR-487b, very likely owing to the small number of stage 4 patients <18 months.

Figure 3
Scatter plots showing the statistical analysis of miR-487b, miR-410 and miR-409-3p expression levels in tissue samples of validation test. (A) Validation set tumours (n=214) stratified in two groups, low-risk (blue, n=142) vs high-risk (red, n=72). ( ...
Table 2
Characteristics of patients and tissues

Next, we investigated whether downregulation of the three selected miRNAs was associated with clinical features. To this aim, the statistical analyses were performed on the global retrospective cohort of the 226 clinically documented patients, by converting the continuous miRNA expression values into a dichotomic variable, low and high expression, as described in Materials and methods. Fisher's exact test indicated that, except for miR-409-3p, downregulation of either miR-487b or miR-410 was well associated with stage and MYCN amplification (P<0.01) (Supplementary Table 5), confirming a link of miR-487b and miR-410, but not miR-409-3p, with the high-risk phenotype. miR-409-3p was thus excluded for further investigations.

Expression of miR-487b and miR-410 as prognostic marker of patient survival

Statistical analyses were performed to determine the significance of miR-487b and miR-410 expression level as prognostic factor. Disease outcome (survival and relapse events) was known for the 227 patients. The final follow-up date was February 2011 with a median follow-up of 92 months (95% CI=79–104). An event (death or relapse) was registered for 90 patients (40%) with death recorded for 68 patients (30%). An univariate Cox proportional hazards regression showed that patients with low expression of either miR-487b or miR-410 had an overall and disease-free survival significantly lower than patients with high expression (Table 3). Consistent with the univariate Cox regression analysis, Kaplan–Meier survival highlighted that patients with high expression levels of miR-487b and miR-410 displayed a better prognosis than did those with low levels both in terms of overall survival and disease-free survival (P<0.0001 and P<0.002, respectively, Figure 4). Two multivariable Cox proportional hazard model analyses were performed to assess whether each miRNA was an independent prognostic factor (Table 3). While miR-410 was not statistically associated to overall survival (HR=1.448 95% CI=0.729–2.875, P=0.29) and disease-free survival (HR=1.614 95% CI=0.926–2.813, P=0.0912), miR-487b was found to be an independent prognostic factor both in overall and in disease-free survival (HR=2.833 95% CI=1.192–6.731, P=0.018 and HR=2.145 95% CI=1.164–3.952, P=0.014, respectively).

Figure 4
Kaplan–Meier curves for overall and disease-free survival of the whole neuroblastoma cohort (n=226) for miR-487b and miR-410 expression. The miRNA expression levels were converted into discrete variables by discriminating the samples into two ...
Table 3
Univariate and multivariable Cox regression analysis of overall and disease-free survival in all neuroblastoma patients (n=226)

In addition to the strong association between miR-487b with either the overall survival or the disease-free survival measured by the hazard ratios (Table 3), Table 4 showed the sensitivity and the specificity of miR-487b predictive ability. The high sensitivities (⩾0.84) within 2, 5 and 8 years indicated the good ability of miR-487b to discriminate between overall survival and disease-free survival. The specificity giving the probability of patients with high expression of miR-487b to be part of the low-risk group was between 34% and 45%.

Table 4
Sensitivity and specificity of the miR-487b marker in all neuroblastoma patients (n=226) with 156 ‘low expression' and 70 ‘high expression'

miR-487b and miR-410 expression predict overall and disease-free survival in low-risk neuroblastoma

Next, the association of the two miRNAs with survival was investigated in the group of high-risk patients (n=80). Kaplan–Meier curves showed a trend of significance regarding the association of miR-487b or miR-410 expression with overall survival (P=0.059) and disease-free survival (P=0.067) (Supplementary Figure 1).

Finally, we investigated the prognostic value of miR-487b and miR-410 expression levels in the subgroup of low-risk patients as defined by non-MYCN-amplified stage 1, 2 and 3 tumours. Kaplan–Meier survival curves revealed that the clinical outcome (overall and disease-free survival) of patients with high expression levels of either miR-487b or miR-410 was strongly correlated with better survival than patients with low expression levels (Figure 5A). Kaplan–Meier survival curves were also performed with the low-risk subgroup defined by non-MYCN-amplified tumours of stage 4 <18 months including stage 4S. Again, irrespective of the small number of samples (n=28), survival curves showed that patients with high expression levels of either miR-487b or miR-410 had a better prognosis in terms of overall and disease-free survival than those with low expression levels (Figure 5B).

Figure 5
Kaplan–Meier curves for overall and disease-free survival of (A) non-MYCN-amplified localised neuroblastoma (n=119) and (B) non-MYCN-amplified stage 4S and 4 neuroblastoma of age <18 months (n=28) for miR-487b and miR-410 expression. The ...


A body of evidence demonstrates that some specific miRNAs can be considered as biomarkers for clinical applications especially for neuroblastoma (Stallings et al, 2010). In the search of a unique miRNA signature able to improve risk classification of these tumours, we identified a set encoded by the chromosome 14q32.31 miRNA cluster locus that was significantly downregulated in high-risk neuroblastoma. We report here that two of them, miR-410 and miR-487, which exhibited the highest fold change were able to discriminate high-risk from low-risk neuroblastoma and could be considered as putative prognostic factors. Moreover, expression of these two miRNAs was significantly associated with the overall survival and disease-free survival in the subgroup of neuroblastoma so far delineated as low-risk.

The wide spectrum of biological and clinical behaviours of neuroblastoma has resulted in basic risk stratification parameters (age, stage and MYCN amplification) that discriminate high-risk from low-risk patients (Cohn et al, 2009; Maris, 2010). However, limitations in this stratification system are generally recognised and addition of prognostic factors might be helpful to provide optimised and personalised neuroblastoma treatment. Most results dealing with miRNA in neuroblastoma concern the identification of miRNAs differentially expressed in MYCN-amplified vs non-MYCN-amplified tumours (Chen and Stallings, 2007; Bray et al, 2009). Dysregulation of some miRNAs encoded by the 14q32.31 locus has been already reported but the relationship between their abnormal expression and the clinical outcome of the disease has not been investigated (Bray et al, 2009). We performed microarray expression profiling on a preliminary cohort of 13 neuroblastoma tumours that allowed identification of 17 downregulated miRNAs that were significant discriminators of high-risk neuroblastoma. Notably, 15 were located at the 14q32.31 chromosomal locus. Three miRNAs were selected for further studies, miR-487b, miR-410, with the highest fold change, and miR-409-3p, with a medium fold change. The significant downregulation of these three miRNAs found in high-risk neuroblastoma was first confirmed by qRT-PCR on the preliminary cohort samples and then validated using an independent cohort of 214 tumours. To investigate the possible clinical use of these three miRNAs as potential biomarkers of aggressiveness, statistical analyses were performed on the whole retrospective cohort of the 227 neuroblastoma patients. Expression values were set up as binary variables coded as 0 for low expression and 1 for high. The results indicated that low expression levels of miR-487b, miR-410 and miR-409-3p were strongly and significantly associated with high-risk phenotype independent of MYCN amplification for miR-487b and miR-410, but not for miR409-3p. Moreover, expression levels of miR-487b were independent of clinical covariates (age, stage and MYCN amplification) associated with overall and disease-free survival in the multivariable model. Then, we surveyed the prognostic impact of miR-487b and miR-410 expression levels in each group of risk; miR-409-3p that was found not associated with non-MYCN-amplified high-risk tumours was not retained for further analyses. In high-risk neuroblastoma (n=80), we found that the expression of each miRNA was associated with overall survival, though with a trend of significance. By contrast, considering the two subgroups of low-risk neuroblastoma, that is, non-MYCN-amplified stage 1, 2 and 3 patients and non-MYCN-amplified stage 4 of infant <18 months, expression levels of both miR-487b and miR-410 displayed a highly significant association with overall and disease-free survival. Thus, our study clearly shows the clinical potential of miR-410 and miR-487b for the non-MYCN-amplified low-risk neuroblastoma. In combination with other markers of relapse, high levels of these two miRNAs could indicate the prescription of treatment des-escalation and low levels escalation. Whether the rest of top-ranked miRNAs of the 14q32.31 set, not considered in the present study, could help to discriminate unfavourable neuroblastoma remains to be investigated.

With regards to the high-risk group (MYCN-amplified and non-MYCN-amplified stage 4 ⩾18 months), the marginal significance of overall survival may be owing to the low number of survivors at 5 years post diagnosis. Noteworthy, most survivors showed a high expression level of miR-487b and miR-410. It remains thus to extend our investigation to a higher number of high-risk neuroblastoma.

From a functional point of view, the fact that 15/17 miRNAs (88%) significantly downregulated in high-risk neuroblastoma are encoded by the 14q32.31 locus suggests a tumour suppressive role for this chromosomal region; this is in agreement with reduced expression levels of these miRNAs measured in aggressive forms of several human cancers (Cobbs et al, 2008; Haller et al, 2010; Lavon et al, 2010). As the largest miRNA cluster identified so far in human (Glazov et al, 2008), the 14q32.31 locus encompasses >40 miRNAs likely encoded in a single pri-miRNA (Tierling et al, 2006). Noteworthy, this genetically imprinted region (Seitz et al, 2004) modulates neuronal responses with some miRNAs shown to have a crucial role in dendritic outgrowth in response to the environment (Khudayberdiev et al, 2009). In the same line of evidence, the mouse homologous region at chromosome 12 has been defined as a cancer susceptibility locus (Sevignani et al, 2007; Kircher et al, 2008). No loss of 14q copy in high-risk neuroblastoma samples suggests that the reduced expression of the encoded miRNAs is likely the result of a transcriptional or processing regulation, in agreement with reports stating the epigenetic transcriptional silencing of this genomic locus (Zhang et al, 2008; Haller et al, 2010; Lavon et al, 2010). Noteworthy, the proved target genes of 14q32.31 miRNAs are involved in numerous key biological functions such as transcription factors (E2F1, HNF-6 and NF-YB), cell cycle regulation (CDK1), proliferation (HER2), stress response (SOD1, 2), cytoskeleton signalling (PAK1) and cell interaction (E-Cadherin), of which dysregulation could lead to malignancy (Supplementary Table 6).

In conclusion, our results point out the involvement of 14q32.31 miRNAs in tumour progression of neuroblastoma. More importantly, our study suggests the potential of two miRNAs, miR-487b and miR-410, as clinically useful markers of both overall survival and disease-free survival in the two clinical entities delineated so far as low-risk, for example, non-MYCN-amplified stage 1, 2 and 3 and non-MYCN-amplified stage 4 <18 months. If our findings can be confirmed in other studies, miR-487b and miR-410 might be integrated as molecular markers in the stratification algorithm under investigation that would enable to optimise the treatment of those patients. To the best of our knowledge, no data are available on the potential of miRNAs to be used as predictors of relapse for low-risk patients and of survival for high-risk patients.


This study was funded by the Ligue contre le Cancer (Comités Oise et Montbéliard), Fédération Enfants et Santé et Société Française de Lutte contre les Cancers et les Leucémies de l'Enfant et de l'Adolescent and Association Princesse Framboise. We thank Dr Françoise Wendling for scientific input and manuscript editing. We thank Dr Marie-Anne Raquin (IGR, Villejuif) for providing clinical annotations of the tumour specimens, Dr Matthieu Bauer for preliminary studies and Anissa Ilias for technical assistance.


Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Material

Supplementary Figure 1

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3

Supplementary Table 4

Supplementary Table 5

Supplementary Table 6

Supplementary Information


  • Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O′Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003;21:2077–2084. [PubMed]
  • Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Benard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Potschger U, Ambros PF. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res. 2011;17:792–804. [PubMed]
  • Benard J, Raguenez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol. 2008;2:261–271. [PubMed]
  • Bettan-Renaud L, Bayle C, Teyssier JR, Benard J. Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835. Int J Cancer. 1989;44:460–466. [PubMed]
  • Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, London WB, McGrady PW, Higgins DG, O′Meara A, O′Sullivan M, Stallings RL. Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS ONE. 2009;4:e7850. [PMC free article] [PubMed]
  • Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216. [PubMed]
  • Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–622. [PubMed]
  • Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67:976–983. [PubMed]
  • Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008;68:724–730. [PubMed]
  • Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–297. [PMC free article] [PubMed]
  • De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A, Castel V, Forjaz dL, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009;27:1034–1040. [PubMed]
  • Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. [PMC free article] [PubMed]
  • Glazov EA, McWilliam S, Barris WC, Dalrymple BP. Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Mol Biol Evol. 2008;25:939–948. [PubMed]
  • Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36:D154–D158. [PMC free article] [PubMed]
  • Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G, Wiemann S, Sahin O. Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol. 2010;220:71–86. [PubMed]
  • Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–344. [PubMed]
  • Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27:1026–1033. [PubMed]
  • Khudayberdiev S, Fiore R, Schratt G. MicroRNA as modulators of neuronal responses. Commun Integr Biol. 2009;2:411–413. [PMC free article] [PubMed]
  • Kircher M, Bock C, Paulsen M. Structural conservation versus functional divergence of maternally expressed microRNAs in the Dlk1/Gtl2 imprinting region. BMC Genomics. 2008;9:346. [PMC free article] [PubMed]
  • Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Cohen MA, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE, Felig Y, Gerlitz O, Ben Hur T, Smith Y, Siegal T. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 2010;12:422–433. [PMC free article] [PubMed]
  • Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, London WB, Chang CH, Yu AL. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010;70:7841–7850. [PMC free article] [PubMed]
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. [PubMed]
  • Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211. [PMC free article] [PubMed]
  • Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264–2279. [PubMed]
  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173. [PubMed]
  • Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29:449–455. [PubMed]
  • Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer. 2008;122:699–704. [PubMed]
  • Schulte JH, Marschall T, Martin M, Rosenstiel P, Mestdagh P, Schlierf S, Thor T, Vandesompele J, Eggert A, Schreiber S, Rahmann S, Schramm A. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res. 2010;38:5919–5928. [PMC free article] [PubMed]
  • Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res. 2004;14:1741–1748. [PMC free article] [PubMed]
  • Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T, Demant P, Croce CM, Siracusa LD. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA. 2007;104:8017–8022. [PMC free article] [PubMed]
  • Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–2075. [PubMed]
  • Stallings RL, Foley NH, Bryan K, Buckley PG, Bray I. Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets. 2010;14:951–962. [PubMed]
  • Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001;36:28–31. [PubMed]
  • Tierling S, Dalbert S, Schoppenhorst S, Tsai CE, Oliger S, Ferguson-Smith AC, Paulsen M, Walter J. High-resolution map and imprinting analysis of the Gtl2-Dnchc1 domain on mouse chromosome 12. Genomics. 2006;87:225–235. [PubMed]
  • Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, Chastagner P, Bouzy J, Hartmann O. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol. 2005;23:532–540. [PubMed]
  • Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Butzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008;105:7004–7009. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence and PMC links.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • MedGen
    Related information in MedGen
  • Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...